Raymond James & Associates increased its stake in Zoetis Inc (NYSE:ZTS) by 8.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 644,165 shares of the company’s stock after purchasing an additional 49,986 shares during the period. Raymond James & Associates owned 0.13% of Zoetis worth $46,407,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Zoetis in the 4th quarter worth approximately $108,000. Steward Partners Investment Advisory LLC acquired a new stake in Zoetis in the 3rd quarter worth approximately $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after purchasing an additional 1,360 shares in the last quarter. Premia Global Advisors LLC acquired a new stake in Zoetis in the 4th quarter worth approximately $122,000. Finally, Icon Wealth Partners LLC acquired a new stake in Zoetis in the 4th quarter worth approximately $127,000. Institutional investors own 92.45% of the company’s stock.
Zoetis Inc (NYSE:ZTS) opened at $84.59 on Wednesday. The company has a debt-to-equity ratio of 2.77, a quick ratio of 2.55 and a current ratio of 3.85. The firm has a market cap of $40,960.27, a P/E ratio of 48.34, a PEG ratio of 1.89 and a beta of 0.97. Zoetis Inc has a 1-year low of $52.25 and a 1-year high of $85.54.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be issued a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a dividend yield of 0.60%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s dividend payout ratio (DPR) is 28.57%.
A number of analysts recently commented on ZTS shares. Cowen set a $80.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Friday, November 17th. Morgan Stanley upgraded shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 target price for the company in a research note on Wednesday, November 29th. Cantor Fitzgerald set a $85.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research note on Thursday, January 11th. Citigroup upgraded shares of Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 price objective for the company in a research note on Thursday, January 4th. Finally, UBS Group restated a “neutral” rating on shares of Zoetis in a research note on Friday, November 24th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. Zoetis has an average rating of “Buy” and an average price target of $80.28.
In other news, EVP Roxanne Lagano sold 35,663 shares of Zoetis stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $81.02, for a total transaction of $2,889,416.26. Following the completion of the transaction, the executive vice president now directly owns 49,919 shares of the company’s stock, valued at approximately $4,044,437.38. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Roman Trawicki sold 8,568 shares of Zoetis stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $83.10, for a total transaction of $712,000.80. Following the transaction, the insider now directly owns 11,457 shares of the company’s stock, valued at $952,076.70. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 105,569 shares of company stock valued at $8,594,429. Insiders own 0.31% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Zoetis Inc (ZTS) Position Increased by Raymond James & Associates” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/03/14/zoetis-inc-zts-position-increased-by-raymond-james-associates.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.